Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban

Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban

To estimate the real-world rates of recurrent Venous thromboembolism (VTE), major bleeding and all-cause mortality in patients with Cancer-associated thrombosis (CAT) treated with rivaroxaban

Inclusion Criteria:

• Adult patients (≥18 years-of-age) with active cancer
• Patient with at least one index venous thromboembolism (VTE )
• ≥6-months of continuous eligibility prior to the index VTE event (baseline period).
• Newly initiated on rivaroxaban

Exclusion Criteria:

• Patients with any medical claim for Deep vein thrombosis (DVT) or Pulmonary embolism (PE) during the 6 months pre-index date
• Patients with prescription claim for anticoagulation therapy during the 6-month pre-index VTE period